152459-85-3

Basic information

• Product Name: N-(3-nitrophenyl)-4-(pyridin-4-yl)-2-pyrimidine-amine
• Synonyms: N-(3-nitrophenyl)-4-(pyridin-4-yl)-2-pyrimidine-amine
• CAS NO: 152459-85-3
• Molecular Weight: 293.285
• Mol File: 152459-85-3.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: N-(3-nitrophenyl)-4-(pyridin-4-yl)-2-pyrimidine-amine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-nitrophenyl)-4-(pyridin-4-yl)-2-pyrimidine-amine(152459-85-3)
• EPA Substance Registry System: N-(3-nitrophenyl)-4-(pyridin-4-yl)-2-pyrimidine-amine(152459-85-3)

Safety Data

• Hazardous Substances Data: 152459-85-3(Hazardous Substances Data)

Upstream product

• 24067-37-6 N-(3-Nitrophenyl)guanidine 
• 123367-27-1 (E)-3-(dimethylamino)-1-(pyridin-4-yl)prop-2-en-1-one 
• 142992-99-2 N-(3-nitro-phenyl)-guanidine nitrate 

Relevant articles and documents

Potent and selective inhibitors of the Abl-kinase: Phenylaminopyrimidine (PAP) derivatives

Due to its relatively clear etiology, chronic myelogenous leukemia (CML) represents an ideal disease target for a therapy using a selective inhibitor of the Bcr-Abl tyrosine protein kinase. Extensive optimization of the class of phenylamino-pyrimidines yielded highly potent and selective Bcr-Abl kinase inhibitors. Compound 1 shows high potency (IC50 = 38 nM) and selectivity for the Abl tyrosine protein kinase at the in vitro level.

Pyrimidine Derivatives

-

Phenylamino-pyrimidine (PAP) derivatives: A new class of potent and selective inhibitors of protein kinase C (PKC)

Phenylamino-pyrimidines represent a novel class of inhibitors of the protein kinase C with a high degree of selectivity versus other serine/threonine and tyrosine kinases. Steady state kinetic analysis of N-(3-[1-imidazolyl]-phenyl)-4-(3-pyridyl)-2-pyrimidinamine (5), which showed potent inhibitory activity, revealed competitive kinetics relative to ATP. The adjacent H-bond acceptor of the pyrimidine moiety next to an H-bond donor of the phenylamine was found to be crucial for inhibitory activity. N-(3-Nitro-phenyl)-4-(3-pyridyl)-2-pyrimidinamine (7) preferentially inhibited PKC-α (IC50 = 0.79 μM) and not the other subtypes tested. The inhibition constants of PKC-α and the antiproliferative effect on T24 human bladder carcinoma cells showed a qualitative correlation, although with some exceptions.